… In general, drug development requires a … drug development is very low (less than 10%)
[8]. Therefore, this kind of traditional drug development is not practical in the current COVID-19 …

… There have been extensive efforts to repurpose approved drugs during the COVID-19
pandemic. A selection of drugs being tested for COVID-19 is presented in Table 1. As an example, …

… we summarize the current state of knowledge surrounding COVID-19 and discuss the
discovery and development of new virus-based and host-based therapeutic options for COVID-19. …

… drugs that are approved for human use based on the mechanisms of drug action that may
also effectively treat COVID-19 allows … of single/combination drug trials to address COVID-19 …

… review will stimulate development of much needed effective drugs against Covid-19. …
In this review, we highlight the potential drug development targets, protein X-ray structure-based …

… drugs to combat any disease. The discovery of novel targets for COVID-19 using computer-aided
drug … computational tools to discover suitable drugs for COVID-19 is also discussed. …

… Due to the fact that this protein is essential for RNA viral synthesis and one of the most
conserved proteins in nidoviruses, it is considered an interesting target for drug development, and …

… The increasing cost of drug development is due to the large volume of compounds to be
tested in preclinical stages and the high proportion of randomised controlled trials (RCTs) that …

… The IO field continues to grow, with more drugs and trials for almost all IO drug classes …
As our analysis captures the height of the COVID-19 pandemic in April 2020, it indicates …

… of 3CLpro can make it a promising drug development target for COVID-19. Therefore, anti-bacterial
drugs such as lymecycline and anti-hypertensive drugs such as nicardipine are all …